{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:43:06Z","timestamp":1793835786513,"version":"4.6.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To perform a systematic review and meta-analysis evaluating the efficacy of adjuvant human papillomavirus (HPV) vaccination in preventing recurrent cervical intraepithelial neoplasia (CIN) 2 or greater after surgical excision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Electronic databases (Cochrane, PubMed, EMBASE, MEDLINE, Scopus, and ClinicalTrials.gov) were searched for studies comparing surgical excision alone to surgical excision with adjuvant HPV vaccination for CIN 2 or greater. Studies published from January 1990 to January 2019 were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>A total of 5,901 studies were reviewed. The primary outcomes evaluated included: recurrence of CIN 2 or greater, CIN 1 or greater, and HPV 16,18 associated CIN within 6\u201348 months. We used Covidence software to assist with screening, and meta-analysis was performed using Review Manager.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TABULATION, INTEGRATION, AND RESULTS:<\/jats:title>\n                    <jats:p>Six studies met inclusion criteria and were included in the final analysis. In total 2,984 women were included; 1,360 (45.6%) received adjuvant HPV vaccination after surgical excision, and 1,624 (54.4%) received either placebo or surgical management alone for CIN 2 or greater. Recurrence of CIN 2 or greater occurred within 6\u201348 months in 115 women (3.9%) overall; however, recurrence was significantly lower for vaccinated women: 26 of 1,360 women (1.9%) vs 89 of 1,624 unvaccinated women (5.9%) (relative risk [RR] 0.36 95% CI 0.23\u20130.55). The risk of CIN 1 or greater was also significantly lower with adjuvant HPV vaccination, occurring in 86 of 1,360 vaccinated women (6.3%) vs 157 of 1,624 unvaccinated women (9.7%) (RR 0.67 95% CI 0.52\u20130.85). Thirty-five women developed recurrent CIN 2 or greater lesions specific to HPV 16,18; nine received adjuvant vaccination (0.9%) vs 26 who were unvaccinated (2.0%) (RR 0.41 95% CI 0.20\u20130.85).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Adjuvant HPV vaccination in the setting of surgical excision for CIN 2 or greater is associated with a reduced risk of recurrent cervical dysplasia overall and a reduction in the risk of recurrent lesions caused by the most oncogenic strains (HPV 16,18). Human papillomavirus vaccination should therefore be considered for adjuvant treatment in patients undergoing surgical excision for CIN 2 or greater.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SYSTEMATIC REVIEW REGISTRATION:<\/jats:title>\n                    <jats:p>PROSPERO, CRD42019123786.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000003833","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T16:26:56Z","timestamp":1586536016000},"page":"1070-1083","source":"Crossref","is-referenced-by-count":85,"title":["Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women"],"prefix":"10.1097","volume":"135","author":[{"given":"Katie","family":"Lichter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Huang Laurent","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Weston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahizechukwu","family":"Eke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Levinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1080\/21645515.2015.1088616","article-title":"Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease","volume":"12","author":"Radley","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/92.9.709","article-title":"Evidence for a causal association between human papillomavirus and a subset of head and neck cancers","volume":"92","author":"Gillison","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.virol.2008.10.004","article-title":"Interaction of human papillomaviruses with the host immune system: a well evolved relationship","volume":"384","author":"Frazer","year":"2009","journal-title":"Virology"},{"issue":"suppl 1","key":"R6-20230711","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijgo.2015.02.014","article-title":"HPV vaccination: the most pragmatic cervical cancer primary prevention strategy","volume":"131","author":"Sankaranarayanan","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cmi.2015.05.001","article-title":"From the monovalent to the nine-valent HPV vaccine","volume":"21","author":"Pils","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"718","DOI":"10.15585\/mmwr.mm6833a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years\u2014United States 2018","volume":"68","author":"Walker","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000356183","article-title":"Vaccines and immunization against human papillomavirus","volume":"45","author":"Christensen","year":"2014","journal-title":"Curr Probl Dermatol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1016\/j.vaccine.2015.04.016","article-title":"Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: results from a longitudinal Dutch cohort study","volume":"33","author":"Mollers","year":"2015","journal-title":"Vaccine"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.pop.2018.10.011","article-title":"Cervical cancer and its precursors: a Preventative approach to screening, diagnosis, and management","volume":"46","author":"Stumbar","year":"2018","journal-title":"Prim Care Clin Off Pract"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1470-2045(11)70078-X","article-title":"Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study","volume":"12","author":"Kocken","year":"2011","journal-title":"Lancet Oncol"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"75","DOI":"10.18438\/B8WS5N","article-title":"Formulating the evidence based practice question: a review of the frameworks","volume":"6","author":"Davies","year":"2011","journal-title":"Evid Based Libr Inf Pract"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","article-title":"Efficacy and other milestones for human papillomavirus vaccine introduction","volume":"23","author":"Pagliusi","year":"2004","journal-title":"Vaccine"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"212.e1","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","volume":"215","author":"Hildesheim","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2\u20133)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int J Cancer"},{"key":"R29-20230711","first-page":"125","article-title":"Minimally invasive surgery with the complementing immunotherapy in the treatment of intraepithelial neoplasia of cervix in women of child-bearing age","volume":"14","author":"Grze\u015b","year":"2011","journal-title":"Onkologia Polska"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"R31-20230711","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"R32-20230711","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1016\/j.vaccine.2014.06.038","article-title":"Efficacy of the HPV-16\/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16\/18 vaccine trial","volume":"32","author":"Hildesheim","year":"2014","journal-title":"Vaccine"},{"key":"R33-20230711","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discov"},{"key":"R34-20230711","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"key":"R35-20230711","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R36-20230711","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ijc.28119","article-title":"Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study","volume":"133","author":"Scott","year":"2013","journal-title":"Int J Cancer"},{"key":"R37-20230711","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2015.11.026","article-title":"A pilot study of pNGVL4a-CRT\/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2\/3 (CIN2\/3)","volume":"140","author":"Alvarez","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R38-20230711","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1078-0432.CCR-08-1725","article-title":"A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2\/3","volume":"15","author":"Trimble","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R39-20230711","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial.","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T17:15:00Z","timestamp":1689095700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003833"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003833","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}